Elevance Health, Inc. (NYSE:ELV) Shares Sold by Duncker Streett & Co. Inc.

Duncker Streett & Co. Inc. lowered its stake in shares of Elevance Health, Inc. (NYSE:ELV - Free Report) by 89.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 150 shares of the company's stock after selling 1,342 shares during the quarter. Duncker Streett & Co. Inc.'s holdings in Elevance Health were worth $55,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Mutual Advisors LLC grew its holdings in shares of Elevance Health by 2.5% in the fourth quarter. Mutual Advisors LLC now owns 2,163 shares of the company's stock worth $833,000 after acquiring an additional 52 shares during the period. Czech National Bank lifted its position in shares of Elevance Health by 6.5% in the fourth quarter. Czech National Bank now owns 50,286 shares of the company's stock worth $18,551,000 after buying an additional 3,049 shares in the last quarter. Benjamin Edwards Inc. lifted its position in shares of Elevance Health by 1,711.9% in the third quarter. Benjamin Edwards Inc. now owns 53,559 shares of the company's stock worth $27,858,000 after buying an additional 50,603 shares in the last quarter. Diversified Trust Co lifted its position in shares of Elevance Health by 13.7% in the fourth quarter. Diversified Trust Co now owns 22,576 shares of the company's stock worth $8,328,000 after buying an additional 2,725 shares in the last quarter. Finally, JB Capital LLC raised its position in Elevance Health by 597.2% during the fourth quarter. JB Capital LLC now owns 9,384 shares of the company's stock valued at $3,462,000 after purchasing an additional 8,038 shares during the period. Hedge funds and other institutional investors own 89.24% of the company's stock.

Insider Activity at Elevance Health

In other Elevance Health news, EVP Charles Morgan Kendrick, Jr. sold 3,504 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $396.30, for a total transaction of $1,388,635.20. Following the sale, the executive vice president now directly owns 10,116 shares in the company, valued at $4,008,970.80. This represents a 25.73 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. 0.35% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of analysts have commented on the company. Argus reaffirmed a "hold" rating and set a $405.40 price target on shares of Elevance Health in a research report on Wednesday, January 29th. Wells Fargo & Company decreased their price objective on Elevance Health from $483.00 to $478.00 and set an "overweight" rating on the stock in a report on Tuesday, January 28th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $485.00 price target on shares of Elevance Health in a report on Friday, January 24th. Barclays increased their price target on shares of Elevance Health from $501.00 to $512.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Finally, StockNews.com raised shares of Elevance Health from a "hold" rating to a "buy" rating in a research note on Saturday, March 1st. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $517.03.

Elevance Health Stock Performance

Shares of NYSE:ELV traded up $1.27 during trading on Thursday, reaching $398.74. 492,879 shares of the company's stock traded hands, compared to its average volume of 1,581,935. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.45 and a quick ratio of 1.50. The company has a 50 day moving average of $389.26 and a 200-day moving average of $436.03. The stock has a market capitalization of $90.65 billion, a P/E ratio of 15.58, a price-to-earnings-growth ratio of 1.18 and a beta of 0.83. Elevance Health, Inc. has a 12 month low of $362.21 and a 12 month high of $567.26.

Elevance Health (NYSE:ELV - Get Free Report) last issued its quarterly earnings results on Thursday, January 23rd. The company reported $3.84 earnings per share for the quarter, beating analysts' consensus estimates of $3.80 by $0.04. Elevance Health had a net margin of 3.38% and a return on equity of 18.28%. On average, equities analysts expect that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 25th. Shareholders of record on Monday, March 10th will be paid a $1.71 dividend. The ex-dividend date is Monday, March 10th. This represents a $6.84 annualized dividend and a yield of 1.72%. This is an increase from Elevance Health's previous quarterly dividend of $1.63. Elevance Health's dividend payout ratio (DPR) is currently 26.71%.

Elevance Health Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.